Table 1.

Prespecified primary and exploratory subpopulations

Subpopulation	Category	Disease progression	≥20% of patients
Primary subpopulations
MAO-B inhibitor at baseline	Yes	Faster	Yes
	No	Slower	Yes
Hoehn and Yahr stage	2	Faster	Yes
	1	Slower	Yes
RBDSQ	≥5	Faster	Yes
	<5	Slower	Yes
Data-driven subphenotypes	Diffuse malignant	Faster	Yes
	Nondiffuse malignant	Slower	Yes
α-synuclein skin (staining by IHC on skin biopsy sections at baseline)a	Yes	Faster	No
	No	Slower	No
DaT-SPECT SBR (ipsilateral putamen)b	Very abnormal	Faster	No
	Abnormal	Slower	No
Exploratory subpopulations
Age at baseline	≥60 years	Faster	Yes
	<60 years	Slower	Yes
Sex	Male	Faster	Yes
	Female	Slower	Yes
Disease duration	>12 months	Faster	Yes
	<12 months	Slower	Yes
Age at diagnosis	≥60 years	Faster	Yes
	<60 years	Slower	Yes
Atrophy in the nucleus basalis of Meynert	Yes	Faster	No
	No	Slower	No
MoCA total score	<22	Faster	No
	>22	Slower	No
GBA mutationc	Yes	Faster	Nob
	No	Slower	Nob
Motor subphenotypes I	Akinetic–rigid	Faster	Yes
	Tremor-dominant	Slower	Yes
Motor subphenotypes II	PIGD	Faster	Yes
	Tremor-dominant	Slower	Yes

^aNote that these data may be confounded by technical pre-processing issues.

^bDefined on the baseline data with a validated cutoff of 0.6.

^cFor the glucocerebrosidase (GBA) mutation subgroup, a 15% sample cutoff was prespecified because very few participants were expected to carry the mutation.

DaT-SPECT, dopamine transporter-single-photon emission computed tomography; IHC, immunohistochemistry; MAO-B, monoamine oxidase-B; MoCA, Montreal Cognitive Assessment; PIGD, postural instability gait dysfunction; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire; SBR, striatal binding ratio.